Literature DB >> 30741178

Death: The Simple Clinical Trial Endpoint.

Eric L Eisenstein1, Kristi Prather1, Stephen J Greene1, Tina Harding1, Amanda Harrington1, Davera Gabriel1, Ingrid Jones1, Robert J Mentz1, Eric J Velazquez2, Kevin J Anstrom1.   

Abstract

Death, as a biological phenomenon, is well understood and a commonly employed endpoint for clinical trials. However, death identification and adjudication may be difficult for pragmatic clinical trials (PCT) that rely upon electronic health record and patient reported data. We propose a novel death identification and verification approach that is being used in the ToRsemide compArisoN with furoSemide FOR Management of Heart Failure (TRANSFORM-HF) PCT. We describe our hybrid approach that includes gathering information from clinical trial sites, a centralized call center, and National Death Index searches. Our methods detail how a possible death is triggered from each of these components and the types of information we require to verify a triggered death. Our different trigger/verification elements collectively define the TRANSFORM-HF PCT's definition of a death event.

Entities:  

Keywords:  clinical trial; death; heart failure; national death index

Mesh:

Substances:

Year:  2019        PMID: 30741178

Source DB:  PubMed          Journal:  Stud Health Technol Inform        ISSN: 0926-9630


  1 in total

1.  Ascertaining Nonfatal Endpoints in Clinical Trials: Central Adjudication Versus Patient Insurance Claims.

Authors:  Eric L Eisenstein; Meredith N Zozus; Sharon F Terry; Linda Davidson-Ray; Kevin J Anstrom
Journal:  Ther Innov Regul Sci       Date:  2021-07-06       Impact factor: 1.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.